Trials / Active Not Recruiting
Active Not RecruitingNCT06347159
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Adults With Hypertrophic Cardiomyopathy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Edgewise Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDG-7500 | Liquid suspension formulation of EDG-7500 |
| DRUG | EDG-7500 | Solid oral formulation of EDG-7500 |
Timeline
- Start date
- 2024-04-11
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2024-04-04
- Last updated
- 2026-02-27
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06347159. Inclusion in this directory is not an endorsement.